Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib Combined With Chemotherapy for Osteosarcoma
NCT06217003Phase 2Not yet recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in osteosarcoma (OS), sponsored by Xinxiang Medical University First Affiliated Hospital. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06217003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217003.